Leiden, The Netherlands, April 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutchbiopharmaceutical company focusing on rare diseases with a highunmet medical need, today announced that Michael S. Wyzga has beennominated for appointment to its Supervisory Board at the nextshareholders' meeting, scheduled for June 17, 2014. "We welcome Michael as an instrumental additionto our Supervisory Board," said Hans Schikan, Prosensa's CEO. "Michael's extensive financial and transactional expertise willsupport the company significantly in our efforts to bringmuch-needed, life-saving treatments for rare genetic diseases topatients. His long-term tenure at Genzyme, one of the mostsuccessful companies in the rare disease space, will be invaluableas we continue developing therapies for boys with Duchenne musculardystrophy and building our company." Mr. Wyzga most recently served as President andChief Executive Officer of Radius Health. Prior to joining Radius,Mr. Wyzga was Executive Vice President and Chief Financial Officerof Genzyme Corporation until its $20.1 billion acquisition bySanofi in April 2011. He joined Genzyme in 1998 and held primaryresponsibility for the company's financial management worldwide.Mr. Wyzga currently serves on the board of directors for OncoMedPharmaceuticals, Akebia Therapeutics and IdenixPharmaceuticals. "Michael's corporate leadership experience inrare diseases makes him an ideal fit for Prosensa, and hiscontribution will be vital as the company works to successfullyadvance its DMD drug pipeline," said David Mott, Chairman ofProsensa's Supervisory Board. "I am pleased to join Prosensa at such asignificant moment in the company's history and look forward toworking alongside a world-class team with exceptional leadership inrare diseases," said Michael Wyzga. "It is an honor to be able toshare my experience and contribute to the future direction andgrowth of a company working so diligently to find a therapeuticoption for boys with this devastating disease."
Notes to editorsAbout Prosensa Holding N.V. Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engagedin the discovery and development of RNA-modulating therapeutics forthe treatment of genetic disorders. Its primary focus is on rareneuromuscular and neurodegenerative disorders with a large unmetmedical need, including Duchenne muscular dystrophy (DMD), myotonicdystrophy and Huntington's disease. Prosensa's current portfolio includes six compounds for thetreatment of DMD, all of which have received orphan drug status inthe United States and the European Union. The compounds use aninnovative technique called exon-skipping to provide a personalizedmedicine approach to treat different populations of DMD patients. www.prosensa.com
CONTACT: Prosensa Holding N.V. Celia Economides, Senior Director, IR & Corporate Communications Phone: +1 917 941 9059 Email: email@example.com